Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 154

1.

Route of administration affects the ability of naltrexone to reduce amphetamine-potentiated brain stimulation reward in rats.

Todtenkopf MS, O'Neill KS, Kriksciukaite K, Turncliff RZ, Dean RL, Ostrovsky-Day I, Deaver DR.

Addict Biol. 2009 Sep;14(4):408-18. doi: 10.1111/j.1369-1600.2009.00161.x. Epub 2009 Jun 1.

PMID:
19489752
2.

Effects of acute oral naltrexone on the subjective and physiological effects of oral D-amphetamine and smoked cocaine in cocaine abusers.

Comer SD, Mogali S, Saccone PA, Askalsky P, Martinez D, Walker EA, Jones JD, Vosburg SK, Cooper ZD, Roux P, Sullivan MA, Manubay JM, Rubin E, Pines A, Berkower EL, Haney M, Foltin RW.

Neuropsychopharmacology. 2013 Nov;38(12):2427-38. doi: 10.1038/npp.2013.143. Epub 2013 Jun 5.

3.

Naltrexone attenuates amphetamine-induced locomotor sensitization in the rat.

Häggkvist J, Björkholm C, Steensland P, Lindholm S, Franck J, Schilström B.

Addict Biol. 2011 Jan;16(1):20-9. doi: 10.1111/j.1369-1600.2009.00199.x.

PMID:
20192948
4.

The effect of naltrexone on amphetamine-induced conditioned place preference and locomotor behaviour in the rat.

Häggkvist J, Lindholm S, Franck J.

Addict Biol. 2009 Jul;14(3):260-9. doi: 10.1111/j.1369-1600.2009.00150.x. Epub 2009 Mar 5.

PMID:
19298318
6.

Naltrexone attenuates the subjective effects of amphetamine in patients with amphetamine dependence.

Jayaram-Lindström N, Konstenius M, Eksborg S, Beck O, Hammarberg A, Franck J.

Neuropsychopharmacology. 2008 Jul;33(8):1856-63. Epub 2007 Oct 24.

7.

Separate and combined impact of acute naltrexone and alprazolam on subjective and physiological effects of oral d-amphetamine in stimulant users.

Marks KR, Lile JA, Stoops WW, Rush CR.

Psychopharmacology (Berl). 2014 Jul;231(14):2741-50. doi: 10.1007/s00213-014-3449-x. Epub 2014 Jan 25.

8.

The opioid receptor antagonist naltrexone attenuates reinstatement of amphetamine drug-seeking in the rat.

Häggkvist J, Lindholm S, Franck J.

Behav Brain Res. 2009 Jan 30;197(1):219-24. doi: 10.1016/j.bbr.2008.08.021. Epub 2008 Aug 28.

PMID:
18793682
10.

Effects of naltrexone on amphetamine-induced locomotion and rearing: acute and repeated injections.

Balcells-Olivero M, Vezina P.

Psychopharmacology (Berl). 1997 Jun;131(3):230-8.

PMID:
9203233
11.

Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial.

Krupitsky E, Nunes EV, Ling W, Illeperuma A, Gastfriend DR, Silverman BL.

Lancet. 2011 Apr 30;377(9776):1506-13. doi: 10.1016/S0140-6736(11)60358-9.

PMID:
21529928
12.

Effects of central leptin infusion on the reward-potentiating effect of D-amphetamine.

Hao J, Cabeza de Vaca S, Pan Y, Carr KD.

Brain Res. 2006 May 4;1087(1):123-33. Epub 2006 Apr 5.

PMID:
16600190
13.

Potency of naltrexone to reduce ethanol self-administration in rats is greater for subcutaneous versus intraperitoneal injection.

Williams KL, Broadbridge CL.

Alcohol. 2009 Mar;43(2):119-26. doi: 10.1016/j.alcohol.2008.11.003.

14.

Effects of mood stabilizers on brain reward processes in rats: studies using the intracranial self-stimulation paradigm.

Mavrikaki M, Nomikos GG, Panagis G.

Eur Neuropsychopharmacol. 2009 Mar;19(3):205-14. doi: 10.1016/j.euroneuro.2008.11.002. Epub 2008 Dec 24.

PMID:
19110403
15.

Efficacy of the atypical antipsychotic aripiprazole in d-amphetamine-based preclinical models of mania.

Mavrikaki M, Nomikos GG, Panagis G.

Int J Neuropsychopharmacol. 2010 May;13(4):541-8. doi: 10.1017/S1461145709991143. Epub 2010 Jan 5.

PMID:
20047715
16.

Isradipine combined with naltrexone persistently reduces the reward-relevant effects of cocaine and alcohol.

Cramer CM, Gardell LR, Boedeker KL, Harris JR, Hubbell CL, Reid LD.

Pharmacol Biochem Behav. 1998 Jun;60(2):345-56.

PMID:
9632216
17.

Repeated electroconvulsive shock attenuates the depressive-like effects of d-amphetamine withdrawal on brain reward function in rats.

Barr AM, Zis AP, Phillips AG.

Psychopharmacology (Berl). 2002 Jan;159(2):196-202. Epub 2001 Sep 22.

PMID:
11862349
18.

Overriding the blockade of antinociceptive actions of opioids in rats treated with extended-release naltrexone.

Dean RL, Todtenkopf MS, Deaver DR, Arastu MF, Dong N, Reitano K, O'Driscoll K, Kriksciukaite K, Gastfriend DR.

Pharmacol Biochem Behav. 2008 Jun;89(4):515-22. doi: 10.1016/j.pbb.2008.02.006. Epub 2008 Feb 11.

PMID:
18342360
19.

Extended-Release Injectable Naltrexone (XR-NTX) With Intensive Psychosocial Therapy for Amphetamine-Dependent Persons Seeking Treatment: A Placebo-Controlled Trial.

Runarsdottir V, Hansdottir I, Tyrfingsson T, Einarsson M, Dugosh K, Royer-Malvestuto C, Pettinati H, Khalsa J, Woody GE.

J Addict Med. 2017 May/Jun;11(3):197-204. doi: 10.1097/ADM.0000000000000297.

PMID:
28379861
20.

Extended-release naltrexone (XR-NTX) attenuates brain responses to alcohol cues in alcohol-dependent volunteers: a bold FMRI study.

Lukas SE, Lowen SB, Lindsey KP, Conn N, Tartarini W, Rodolico J, Mallya G, Palmer C, Penetar DM.

Neuroimage. 2013 Sep;78:176-85. doi: 10.1016/j.neuroimage.2013.03.055. Epub 2013 Apr 6.

Supplemental Content

Support Center